12 March 2019

Contents

Editorial

• 13 March 2019: vol 20 no 3 – first CROI reports

Supplements

• i-Base Fit for Purpose report launched at CROI 2019

Conference reports

• Conference on Retroviruses and Opportunistic Infections (CROI 2019): early reports

• UK patient likely to be the second person cured of HIV: two further cases at CROI 2019 of HIV remission after allogenic stem cell transplants

• Phase 3 results with dual therapy cabotegravir/rilpivirine long-acting injections: ATLAS and FLAIR studies

• Viral reservoir can explain persistent low level viraemia with good adherence on ART

• Dolutegravir suppresses viral load faster than efavirenz in late pregnancy: results from DolPHIN-2

• Raltegravir achieves swifter viral load suppression in pregnancy than efavirenz

• New option for PrEP – TAF/FTC is non-inferior to TDF/FTC: results of phase 3 DISCOVER study

• Dolutegravir can be given with 3HP to prevent TB without dose adjustment

• Double doses of darunavir given with rifampicin lead to high rates of hepatoxicity

• Shared housing compared to living alone: higher CD4, lower viral load and reduced inflammation in macaques

• Selected webcasts at CROI 2019

• Pre-CROI Community HIV Cure Workshop 2019

Research studies

• US requires informed consent forms for clinical studies to be posted online

On the web

• Reports from cure strategies meetings

PDFs

• 13 March 2019 vol 20 no 3